From the clip:
“We are excited to test sozinibercept in large P3 programmes […] with the goal of […] showing that we can improve visual acuity hopefully by up to 5 letters or more.“
To my memory, this is the first time somebody sharing responsibility for running the trials dares to explicitly mention a „5 letters or more“ improvement as what OPT internally is really hoping for. If this hope materializes then Eichenbaum is absolutely right saying that sozinibercept would disrupt the wAMD market.
I just cannot believe existing players continuing to stay quiet with this disruptive opportunity being up for sale / partnership just 15 months ahead of P3 results. Therefore, I’d indeed expect a partnership occurring over the next 3 months being more probable than a classic CR.
From the clip:“We are excited to test sozinibercept in large P3...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
64.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $424.1M | |||
| Open | High | Low | Value | Volume |
| 63.0¢ | 64.0¢ | 62.0¢ | $54.33K | 86.60K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 36038 | 62.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 64.0¢ | 8970 | 1 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
62.8¢ |
Change
0.000 ( 1.18 %) |
||||
| Open | High | Low | Volume | ||
| 62.5¢ | 63.0¢ | 62.0¢ | 15047 | ||
| Last updated 15.59pm 24/05/2024 ? | |||||
| OPT (ASX) Chart |